Vicuron Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, manufacture, and marketing of pharmaceutical products for the treatment of seriously ill patients. Its lead products are in Phase III clinical trials and include anidulafungin, a novel antifungal agent; and dalbavancin, a novel intravenous antibiotic for the treatment of serious Gram-positive infections. The company�s products also include ramoplanin, which is an oral nonabsorbable form of antibiotic that selectively inhibits Gram-positive bacteria, and various types of vancomycin-resistant enterococci and Clostridia. In addition, it provides VIC-Acne, a topical antibiotic cream that is in Phase I clinical trail. Vicuron Pharmaceuticals has research collaboration agreements with Novartis Pharma AG to develop deformylase inhibitors as new antibacterial agents and to provide target-based screens; and Pfizer, Inc. to discover second and third generation oxazolidinones. The company was incorporated as Versicor, Inc. in 1995 and changed its name to Vicuron Pharmaceuticals, Inc. in 2003. Vicuron Pharmaceuticals is headquartered in King of Prussia, Pennsylvania. Vicuron Pharmaceuticals Inc. is a former subsidiary of Pfizer Inc.

Xellia Pharmaceuticals is a specialty pharmaceutical company focused on providing clinically effective anti-infective treatments against serious and often life-threatening infections. With over 100 years of pharmaceutical industry expertise, we are a leading developer, manufacturer and trusted supplier of fermented and semi-synthetic Active Pharmaceutical Ingredients (APIs) and finished dosage forms (FDF), and the world-leading supplier of Vancomycin and Colistimethate Sodium (CMS). Our range of anti-infective treatments combat, most types of bacterial and antibiotic-resistant infections and certain fungal diseases. We have growing sales in more than 70 countries to over 700 customers and are continually developing and expanding our product range to meet new treatment needs and to better service our customers’ requirements. This includes developing new dosage forms using Xellia’s APIs, and if required APIs sourced from our network of suppliers. To complement our dry powder fill and freeze-dried vials for injectable delivery we are also developing innovative proprietary delivery systems and formulations for topical, inhaled or injectable administration either in house or through partnerships. We also offer contract manufacturing services and custom synthesis for clinical trial material supply. Xellia is a private company, with more than 850 employees and four state-of-the-art manufacturing facilities in Norway, Denmark, Hungary and China. We operate according to current Good Manufacturing Practice (cGMP) and our facilities have received regulatory approval from all relevant authorities, including the US Food and Drug Administration (FDA). Our operational headquarters are in Copenhagen, Denmark.

Kunming Institute of Zoology (KIZ) (中国科学院昆明动物研究所), one of the 20 biological institutes under the Chinese Academy of Sciences (CAS), is one of China's first class zoological research institutes, located in Kunming, Yunnan province. The Institute has access to the unique and diversified animal resources of the Eastern Himalayas as well as a wide variety of the species from across Southeast Asia, the southern parts of Yunnan province being part of the Indo-Burma biodiversity hotspot. KIZ focuses on life science research, with research groups including systematic zoology, conservation biology, cytology, molecular biology, genome evolution, reproductive and developmental biology, neurobiology, immunological biology on important virus disease, zoological toxicology and primate biology.

Chongqing Qiantai Biopharmaceutical Co., Ltd., established on 2011-09-06, Business scope includes general items:Technology research and development of biomedical products,technology transfer,technical consulting,Technical Services;Pharmaceutical Intermediates(Free of chemical hazards,Psychological narcotics and other items that have special regulations in the country)research and development,Sales and technical consultation,Technical Services;Import and export,Technology Import and Export.[business law,Operation prohibited by administrative regulations;law,Projects subject to approval under administrative regulations,Must be approved in accordance with the law before operating]**(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license)

Livzon Group Xinbeijiang Pharmaceutical Manufacturing, Inc. engages in the manufacture of pharmaceutical intermediates, chemical raw materials, and additives. It also involves in research and development, and technical services. The company was founded on March 28, 1993 and is headquartered in Qingyuan, China.

Livzon Group Fuzhou Fuxing Pharmaceutical Co., Ltd., part of Livzon Pharmaceutical Group, Inc., is a company headquartered in Fuzhou, China. The firm manufactures and sells pharmaceutical products. It was founded in 1979.

Gufic Biosciences Ltd. engages in the manufacture and marketing of active pharmaceutical ingredients, generic pharmaceuticals, and related services. It operates through the following geographical segments: India, Africa, Asia, Europe, North America, Australia and South America. The company was founded on July 23, 1984 and is headquartered in Mumbai, India.

Allergan Pharmaceuticals International Ltd., a subsidiary of AbbVie, Inc., is a company headquartered in Ireland. The firm provides legal services.

China State Institute of Pharmaceutical Industry is a Chinese company located in Shanghai and ultimately controlled by the Government of China. The firm regulates pharmaceutical companies.

Lunan New Times Biotechnology Co., Ltd., established on 2007-03-15, Business scope includes biotechnology products,Pharmaceutical Intermediates,Raw materials and preparations,Healthy food,food,Research and Development of Cosmetics,production and sales.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments).

Tianjin Hankang Pharmaceutical Biotechnology Co., Ltd. is a high-tech enterprise with independent intellectual property rights and specialized in R&D, production and sales of pharmaceuticals. In 2009, he was awarded the title of “Tianjin Enterprise Technology Center”. In 2013, he was included in the list of small giant growth companies that the mayor focused on. In 2014, Hankang R&D Center was named “Tianjin Key Laboratory of Enterprises”. 　　Hankang is mainly engaged in the research of new chemical drugs, and the technical sources are all independent research and development. The company has a professional research team, technicians are all undergraduate or above, and at the same time employ many well-known domestic and foreign experts as technical consultants, scientific research results are remarkable. At present, more than 180 products have been successfully developed, more than 40 new drug certificates, more than 90 clinical approvals for new drugs, and more than 40 production approvals. He applied for more than 140 invention patents and obtained more than 60 invention patent certificates. He was awarded Tianjin Tianjin Invention Patent Pilot Enterprise twice.

devie medical GmbH engages in the development, production, and distribution of drug-eluting heart valve. The company was founded in 2018 and is headquartered in Jena, Germany.

Hangzhou Huadong Pharmaceutical Group New Drug Research Institute Co., Ltd., established on 2002-06-12, Business scope includes licensed projects:Internet Information Service for Medical Devices;Class III medical device business(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,Specific business projects are subject to approval results).General project:Cosmetics Wholesale;Cosmetics Retail;internet sales(Except for products that require a license for sale);Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion;Sales of Class II Medical Devices;Production of Class I Medical Devices;Sales of Class I Medical Devices;Medical Research and Experimental Development;Engineering and Technology Research and Experimental Development;Pharmaceutical special equipment sales;Remote Health Management Services;Internet of things technology research and development;R&D of industrial enzyme preparations;Technology Import and Export(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license).

Chengdu Yatu Biotechnology Co. Ltd. is a company headquartered in China. The firm operates a research and development process company for bio-medicines.

Zhejiang Hisun Pharmaceutical Co., Ltd. engages in the research & development, manufacture, and sale of pharmaceutical products as well as veterinary medicines. Its products include active pharmaceutical ingredients and generic drugs. The company was founded in 1956 and is headquartered in Taizhou, China.

Changshu Nano Microorganism Technology Co., Ltd., established on 2015-01-26, Business scope includesPMMAMicrospheres,PSMicrospheres,Production of biotechnology products related to silicon spheres,Sell ​​and provide related technology and after-sales service;researchfor powder materials,Chromatographic material,Efficient separation and purification medium,Polymer microsphere material,Flat Panel Display Raw Materials,light diffusing particlesPMMAMicrospheres,PSMicrospheres,Silicon ball,R & D and design of chromatographic columns and scientific analysis instruments.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments) licensed items:Import and export;Technology Import and Export(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,Specific business projects are subject to approval results) General project:synthetic material manufacturing(Free of Hazardous Chemicals);Manufacturing of bio-based materials(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license)

Yichang East Sunshine Biochemical Pharmaceutical Co., Ltd. engages in development, production, and sales of medical accessories, medical packaging materials, medical devices, additives, active pharmaceutical ingredients (APIs), generic drugs, first generic drugs, biological drugs, and new drugs. The company was founded on November 29, 2018 and is headquartered in Yidu, China.

Northern Antibiotics Oy engages in the discovery and development of novel antibiotics against multidrug-resistant gram-negative bacteria. It develops compounds, which are active against difficult-to-treat gram-negative bacteria, such as multi-resistant Escherichia coli, Klebsiella pneumoniae, other species of Enterobacteriaceae, and Acinetobacter baumannii. The company was founded by Martti Sakari Vaara and Timo Ilmari Vaara in 2003 and is headquartered in Helsinki, Finland.

Spero Therapeutics is developing first in class therapeutics for treatment of gram-negative infections. The company leverages a top-tier chemistry and microbiology team, an efficient virtual approach to drug development, and a focus on high potential, novel mechanisms to fill the unmet need for early stage therapeutics targeting serious bacterial infections. Its lead program addresses a novel target driving virulence and persistence of pseudomonas aeruginosa infections and other gram-negative pathogens.